Hypertension and Cardiovascular Risk Factors

Novartis76 enrolled

Overview

A study to evaluate the efficacy of valsartan+chydochlorothiazide in patients with stage 2 hypertension and cardiovascular risk factors.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

HYPERTENSION

Interventions

VALSARTAN+HYDROCHLOROTHIAZIDEDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \- Patients who give consent * Men and women 18 to 80 years of age * Patients with hypertension (systolic \>159 mm, diastolic \>100 mm) * Patients meeting laboratory criteria Exclusion Criteria: * \- Pregnant women * Women not using approved contraception methods * Secondary hypertension Other protocol-defined exclusion criteria may apply.

Outcomes

Primary Outcomes

Change from baseline systolic blood pressure at 8 weeks

Secondary Outcomes

Blood pressure less than 140/90 mmHg at 8 weeks

Reduction from baseline in diastolic blood pressure greater than or equal to 10 mmHg

Reduction from baseline in systolic blood pressure greater than or equal to 20 mmHg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.